Brainstorm Cell Therapeutics Q2 2026 Earnings Report

Brainstorm Cell Therapeutics EPS Results

• Actual EPS: -$0.35
• Consensus EPS: -$0.29
• Beat/Miss: Missed by -$0.06
• One Year Ago EPS: N/A

Brainstorm Cell Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Brainstorm Cell Therapeutics Announcement Details

• Quarter: Q2 2026
• Date: 8/14/2026
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

Brainstorm Cell Therapeutics (NASDAQ:BCLI) (NASDAQ: BCLI) is a clinical‐stage biotechnology company focused on developing autologous cell therapies for the treatment of neurodegenerative diseases. The company’s proprietary platform leverages mesenchymal stem cells (MSCs) that are engineered to secrete neurotrophic and growth factors designed to support neuronal survival and function.

The company’s lead product candidate, NurOwn, is an autologous MSC therapy currently in advanced clinical development for amyotrophic lateral sclerosis (ALS). NurOwn has received orphan drug designations in multiple jurisdictions and is being evaluated in a pivotal clinical program. In addition to ALS, BrainStorm is exploring potential applications of its cell therapy platform in other neurodegenerative disorders such as multiple sclerosis and Parkinson’s disease.

Founded in 2000 and headquartered in Petach Tikva, Israel, BrainStorm maintains research and development operations as well as a current good manufacturing practice (cGMP) cell‐processing facility. The company also operates an office in New York City, facilitating collaborations with U.S. clinical sites and regulatory agencies. This infrastructure supports late‐stage trials and positions BrainStorm for potential commercial supply should regulatory approval be achieved.

BrainStorm collaborates with leading academic institutions and regulatory authorities to advance its clinical pipeline while maintaining robust data transparency. Guided by a management team with expertise in regenerative medicine, neurology and biopharmaceutical development, the company aims to address significant unmet medical needs in the global neurodegenerative disease market.